Gefitinib is a potent drug used in the treatment of nonsmall-cell lung cancer (NSCLC). Gefitinib acts by inhibition of the epidermal growth factor receptor tyrosine kinase. Clinical trials have confirmed the efficacy of gefitinib for NSCLC. Adverse drug reactions, although frequent, are mild, and include acne-like skin rash and diarrhoea. The present study describes the case of a 56-yr-old male...

background: cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (nsclc). many novel drugs, including gemcitabine, vinorelbine, paclitaxel and docetaxel have been used in combination with cisplatin in this setting. of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. the aim of this study was to evaluate the effi...

Lung cancer, which can be classified into nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is the leading cause of cancerrelated death in the world. NSCLC, which accounts for 80 to 85% of all lung cancers, is distinguished from SCLC by its clinical course and its response to chemotherapy and radiotherapy. More than 70% of NSCLC patients present with unresectable locally adva...

objective(s): although tumor necrosis factor-related apoptosis-inducing ligand (trail) can selectively induce apoptosis in tumor cells, more than half of tumors including non-small cell lung cancer (nsclc) exhibit trail-resistance. the purpose of this study was to determine whether subtoxic-dose cisplatin and trail could synergistically enhance apoptosis on nsclc cells and investigate its under...

background: this study detected osteopontin (opn) and matrix metalloproteinase-7 (mmp-7) expressions to explore the roles of opn and mmp-7 in the occurrence, progression, and prognosis of nonsmall cell lung cancer (nsclc). materials and methods: a retrospective study was conducted on nsclc tissues ( n = 152; case group) and adjacent nonneoplastic lung parenchyma (adjacent to tumor >5 cm; n = 15...

C isplatin (cis-dichlorodiammine-platinum II or CDDP) is the central drug used in the management of thoracic malignancies. The first trials were published in the 1970s [1], showing activity in lung cancer. Since then it has been shown to improve survival in advanced nonsmall cell lung cancer (NSCLC) [2] and survival and cure in combination with radiotherapy in locoregional NSCLC and prior to [3...

Accumulating papers have demonstrated that microRNAs play an important role in the progression of lung cancer, mainly as oncogenic and tumor suppressive. Therefore, microRNAs may influence the survival of lung cancer patients. In this meta-analysis, we evaluated the role of microRNAs in affecting the overall survival in nonsmall cell lung cancer (NSCLC) patients, which may provide valuable info...

Patients with nonsmall cell lung cancer (NSCLC) have been shown to have a higher prevalence of comorbidity associated with age and tobacco consumption. The objective of the present study was to determine the impact of comorbidity on survival after surgery of stage I NSCLC. In total, 588 consecutive patients operated on for a pathological stage I NSCLC between January 1, 1979 and December 31, 20...

Patients with N2 nonsmall cell lung cancer (N2-NSCLC) represent heterogeneous groups. Survivin is a member of the inhibitor of apoptosis family. If N2-NSCLC patients could be stratified, based on survivin expression and/or its relation to cell cycle proteins, into homogeneous subgroups, certain therapies could be selected for those patients. Survivin expression in 78 surgically resected primary...